You are here: Industry Insights > mRNA

News List

COVID-19 vaccination now available for pregnant women between 14 and 36 weeks firstwordpharma
May 31, 2021
Pregnant women between 14 and 36 completed weeks gestation are now being offered an mRNA vaccine (Pfizer or Moderna), following a recent NIAC recommendation.
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline americanpharmaceuticalreview
May 28, 2021
Moderna a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing ...
COVID-19 mRNA vaccines are immunogenic in pregnant and lactating women worldpharmanews
May 19, 2021
Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age women.
mRNA COVID-19 vaccination is immunogenic in the immunocompromised europeanpharmaceuticalreview
May 19, 2021
Research suggests patients who receive COVID-19 vaccines prior to a transplant and subsequent immunosuppression may be protected from the disease.
BioNTech to Establish Regional HQ and Mfg. Facility in Singapore contractpharma
May 11, 2021
New manufacturing site will support global supply of mRNA-based vaccines and therapeutics.
Moderna receives emergency use listing from WHO for Covid-19 vaccine pharmaceutical-technology
May 06, 2021
Moderna has received emergency use listing (EUL) from the World Health Organization (WHO) for its Covid-19 vaccine to prevent the disease in individuals aged 18 years and above.
CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic worldpharmanews
April 26, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV ...
Sanofi Acquires Tidal Therapeutics contractpharma
April 13, 2021
?Sanofi acquired Tidal Therapeutics, a preclinical stage biotech company with a novel mRNA-platform for reprogramming of immune cells, for $160 million upfront and up to $310 million in milestones.
Exacis Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors americanpharmaceuticalreview
April 01, 2021
Exacis Biotherapeutics announced several steps in the preclinical development of its ExaNK? engineered NK cell-therapy candidates.
CureVac, Celonic Enter COVID-19 Vax Mfg. Pact contractpharma
March 31, 2021
Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.